Blood pressure drug tested to prevent transplant complication
NCT ID NCT02338232
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked severe GVHD cases and side effects like low blood pressure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telmisartan (Micardis)
What this could lead to
If it worked, telmisartan could offer a new way to prevent GVHD after stem cell transplants, reducing severe complications.
What could go wrong
The trial was terminated early with only 32 participants, so results are limited. Telmisartan may not be effective or could cause side effects like low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States